Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma

References

• VillanuevaA. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263.
   PubMed Web of Science ®Google Scholar
• Aravinthan AD, Bruni SG, Doyle AC, Thein H-H, Goldaracena N, Issachar A, et al. Liver transplantation is a preferable alternative to palliative therapy for selected patients with advanced hepatocellular carcinoma. Ann Surg Oncol. 2017;24(7):1843–1851.
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi:10.1016/S1470-2045(17)30683-6.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402(6):863–871. doi:10.1007/s00423-017-1609-2.
   PubMed Web of Science ®Google Scholar
• Ettorre GM, Levi Sandri GB, Laurenzi A, Colasanti M, Meniconi RL, Lionetti R, et al. Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation. World J Surg. 2017;41(1):241–249. doi:10.1007/s00268-016-3682-z.
   PubMed Web of Science ®Google Scholar
• Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19(43):7515–7530. doi:10.3748/wjg.v19.i43.7515.
   PubMed Web of Science ®Google Scholar
• Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol. 2015;7(5):738–52. doi:10.4254/wjh.v7.i5.738.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. doi:10.1002/hep.29086.
   PubMed Web of Science ®Google Scholar
• Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol. 2012;56(2):464–473. doi:10.1016/j.jhep.2011.07.012.
   PubMed Web of Science ®Google Scholar
• Kolligs FT, Bilbao JI, Jakobs T, Iñarrairaegui M, Nagel JM, Rodriguez M, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–1721. doi:10.1111/liv.12750.
   PubMed Web of Science ®Google Scholar
• Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155–63 e2. doi:10.1053/j.gastro.2016.08.029.
   PubMed Web of Science ®Google Scholar
• Pinero F, et al. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int. 2016;36(11):1657–67.
   PubMed Web of Science ®Google Scholar
• FacciorussoA, ServiddioG, MuscatielloN. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol. 2016;8(18):770–778. doi:10.4254/wjh.v8.i18.770.
   PubMed Web of Science ®Google Scholar
• LabgaaI, TabrizianP, TitanoJ, KimE, ThungSN, FlormanS, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB. 2019;21(11):1497–1504. doi:10.1016/j.hpb.2019.03.360.
   PubMed Web of Science ®Google Scholar
• Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepat Oncol. 2014;1(3):265–283. doi:10.2217/hep.14.6.
   PubMedGoogle Scholar
• Korean Liver Cancer Association, National Cancer Center. 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut and Liver. 2019;13(3):227–299. doi:10.5009/gnl19024.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507 e2. doi:10.1053/j.gastro.2010.10.049.
   PubMed Web of Science ®Google Scholar
• Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Society of Interventional Radiology Standards of Practice Committee, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28(1):1–15. doi:10.1016/j.jvir.2016.09.024.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132.
   PubMed Web of Science ®Google Scholar
• Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–1152. doi:10.1002/lt.24169.
   PubMed Web of Science ®Google Scholar
• Xiao J, Li G, Lin S, He K, Lai H, Mo X, et al. Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. Int J Clin Exp Pathol. 2014;7(3):1114–1123.
   PubMed Web of Science ®Google Scholar
• Sarbah SA, Gramlich T, Younoszai A, Osmack P, Goormastic M, Grosso L, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2004;49(5):850–853. doi:10.1023/B:DDAS.0000030098.75759.32.
   PubMed Web of Science ®Google Scholar
• N'Kontchou G, Paries J, Htar MTT, Ganne-Carrie N, Costenin L, Grando-Lemaire V, Trinchet J-C, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006;4(8):1062–1068.
   PubMed Web of Science ®Google Scholar
• Tsukioka G, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, et al. Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. WJG. 2006;12(1):48–53. doi:10.3748/wjg.v12.i1.48.
   PubMed Web of Science ®Google Scholar
• Kao W-Y, Chiou Y-Y, Hung H-H, Su C-W, Chou Y-H, Wu J-C, et al. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy. Clin Radiol. 2012;67(5):429–436. doi:10.1016/j.crad.2011.10.009.
   PubMed Web of Science ®Google Scholar
• Chong CC-N, Lee K-f, Ip PC-T, Wong JS-W, Cheung SY-S, Wong J, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? The Surgeon. 2012;10(5):260–266. doi:10.1016/j.surge.2011.07.004.
   PubMed Web of Science ®Google Scholar
• Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014;110(8):2090–2098. doi:10.1038/bjc.2014.130.
   PubMed Web of Science ®Google Scholar
• NomuraF, OhnishiK, TanabeY. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64(8):1700–1707. doi:10.1002/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z.
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Italian Liver Cancer (ITALICA) group, et al. Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterology. 2006;101(3):524–532. doi:10.1111/j.1572-0241.2006.00443.x.
   PubMed Web of Science ®Google Scholar
• Inarrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A, D’Avola D et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol. 2012;38(7):594–601.
   PubMed Web of Science ®Google Scholar
• Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248(4):617–625. doi:10.1097/SLA.0b013e31818a07d4.
   PubMed Web of Science ®Google Scholar
• Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12(47):7561–7567. doi:10.3748/wjg.v12.i47.7561.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826–1837. doi:10.1002/hep.26014.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442. doi:10.1053/jhep.2003.50047.
   PubMed Web of Science ®Google Scholar
• Zhong J-H, Li H, Li L-Q, You X-M, Zhang Y, Zhao Y-N, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38(4):286–295. doi:10.1016/j.ejso.2012.01.006.
   PubMed Web of Science ®Google Scholar